Get 20% lifetime commission for referring investors to digrin.com
here.
Vanda Pharmaceuticals Inc. (VNDA) Financials
VNDA Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 412.5 million | 192.3 million |
| March 31, 2026 | 433.5 million | 152.8 million |
| Dec. 31, 2025 | 488.9 million | 161.8 million |
| Sept. 30, 2025 | 601.1 million | 135.1 million |
VNDA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -81.7 million | 4.7 million |
| March 31, 2026 | -50.4 million | 2.6 million |
| Dec. 31, 2025 | -29.5 million | 2.3 million |
| Sept. 30, 2025 | -31.8 million | 2.1 million |
VNDA Net Income
No data available :(
VNDA Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 170.0 million | - | 22.8 million |
| March 31, 2026 | 202.3 million | - | 13.1 million |
| Dec. 31, 2025 | 263.8 million | - | 12.6 million |
| Sept. 30, 2025 | 293.8 million | - | 10.9 million |
VNDA Shares Outstanding
VNDA Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 411000 | 37.0 million | 71.8 million | - |
| March 31, 2026 | 221000 | 28.4 million | 68.4 million | - |
| Dec. 31, 2025 | 102000 | 29.0 million | 63.0 million | - |
| Sept. 30, 2025 | 161000 | 22.6 million | 60.3 million | - |
VNDA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 50.5 million | 3.6 million |
| March 31, 2026 | 51.7 million | 5.1 million |
| Dec. 31, 2025 | 57.2 million | 3.8 million |
| Sept. 30, 2025 | 56.3 million | 3.0 million |
VNDA Revenue by Segment
Graph available only for paid members. Upgrade to see it.
VNDA
Price: $5.23
52 week price:
Earnings Per Share: -4.70 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 456204
Ebitda: -1.4 millionMarket Capitalization: 303.5 million